Presentations to cover updates across Eikon’s clinical pipeline including:

演示内容将涵盖 Eikon 临床研发管线的最新进展，包括：

Updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of EIK1001, a TLR7/8 dual-agonist, plus pembrolizumab and histology-appropriate chemotherapy in stage 4 non-small cell lung cancer (NSCLC)

来自TeLuRide-005试验的更新数据，该试验是一项正在进行的开放标签II期临床试验，评估TLR7/8双重激动剂EIK1001联合帕博利珠单抗及符合组织学类型的化疗在IV期非小细胞肺癌（NSCLC）患者中的疗效

Updated cohort data from an ongoing Phase 1/2 study of EIK1003, a highly selective non-brain penetrant PARP1 inhibitor, as monotherapy and in combination with chemotherapy in advanced solid tumors

EIK1003（一种高选择性、非脑渗透性PARP1抑制剂）在晚期实体瘤中作为单药治疗及与化疗联合应用的正在进行的1/2期研究的更新队列数据

Initial data from a Phase 1/2 study of EIK1003 in combination with the novel hormonal agent abiraterone in metastatic prostate cancer

EIK1003联合新型激素药物阿比特龙治疗转移性前列腺癌的1/2期研究初步数据

Initial results from an ongoing Phase 1/2 study of EIK1004, a highly selective CNS-penetrant PARP1 inhibitor in advanced solid malignancies

EIK1004（一种高选择性、可穿透中枢神经系统的PARP1抑制剂）治疗晚期实体恶性肿瘤的正在进行的1/2期研究的初步结果

Preliminary safety, tolerability and pharmacokinetic data for EIK1005, a Werner (WRN) helicase inhibitor

EIK1005（一种Werner（WRN）解旋酶抑制剂）的初步安全性、耐受性和药代动力学数据

MILLBRAE, Calif., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the publication of full-text abstracts from its four clinical candidates to be presented at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain beginning on October 23, 2026..

加利福尼亚州米尔布雷，2026年10月18日（环球电讯社）——Eikon Therapeutics, Inc.（纳斯达克股票代码：EIKN）（以下简称“Eikon”）是一家处于后期临床阶段的生物制药公司，致力于开发创新药物以满足尚未被满足的重大医疗需求。该公司今日宣布，其四种临床候选药物的全文摘要将发表于即将于2026年10月23日在西班牙马德里举行的2026年欧洲肿瘤内科学会（ESMO）大会上。

“We are looking forward to sharing updates from across our pipeline at ESMO, with seven abstracts highlighting both new clinical findings, and continued progress in our oncology programs,” said Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon. “Eikon scientists and clinicians look forward to discussing these results with the broader oncology community in Spain.”.

“我们期待在ESMO大会上分享我们研发管线的最新进展，其中七项摘要既突出了新的临床发现，也展示了我们在肿瘤学项目中的持续进展，”Eikon首席执行官兼董事会主席Roger M. Perlmutter医学博士、哲学博士表示。“Eikon的科学家和临床医生期待在西班牙与更广泛的肿瘤学界讨论这些结果。”

2026 ESMO Abstract Titles and Presentation Details:

2026年欧洲肿瘤内科学会（ESMO）摘要标题及报告详情：

EIK1001

EIK1001

Title:

标题：

2664P - TeLuRide-005: Phase 2 study of EIK1001 (TLR7/8 dual agonist) plus pembrolizumab and chemotherapy in patients with stage IV NSCLC: results from the squamous cohort and updated pooled results

2664P - TeLuRide-005：EIK1001（TLR7/8双重激动剂）联合帕博利珠单抗及化疗治疗IV期非小细胞肺癌患者的II期研究：鳞状细胞癌队列结果及更新的汇总结果

Date: Monday, October 26, 2026

日期：2026年10月26日，星期一

Time: 12:00 - 12:45

时间：12:00 - 12:45

Title:

标题：

2724TiP - A Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (NSCLC) [TeLuRide-008]

2724TiP - 一项在IV期非小细胞肺癌（NSCLC）受试者中评估EIK1001联合帕博利珠单抗及化疗的II/3期研究 [TeLuRide-008]

Date: Monday, October 26, 2026

日期：2026年10月26日，星期一

Time: 12:00 - 12:45

时间：12:00 - 12:45

EIK1003

EIK1003

Title:

标题：

1048P - Phase 1/2 study of a PARP1-selective inhibitor, EIK1003, as monotherapy and in combination with paclitaxel (PTX) in advanced solid tumors

1048P - PARP1选择性抑制剂EIK1003作为单药疗法及与紫杉醇（PTX）联合治疗晚期实体瘤的I/II期研究

Date: Friday, October 23, 2026

日期：2026年10月23日，星期五

Time: 15:15 - 16:00

时间：15:15 - 16:00

Title:

标题：

1049P - Phase 1/2 study of a PARP1-selective inhibitor, EIK1003, in combination with abiraterone in patients with metastatic prostate cancer (mPC)

1049P - PARP1选择性抑制剂EIK1003联合阿比特龙治疗转移性前列腺癌（mPC）患者的1/2期研究

Date: Friday, October 23, 2026

日期：2026年10月23日，星期五

Time: 15:15 - 16:00

时间：15:15 - 16:00

EIK1004

EIK1004

Title:

标题：

1060P - A first-in-human Phase 1/2 study of EIK1004, a PARP1-selective CNS-penetrant inhibitor, in patients with advanced solid tumors with HRR mutations

1060P - EIK1004（一种选择性PARP1且能穿透中枢神经系统的抑制剂）在携带HRR突变的晚期实体瘤患者中的首次人体I/II期临床研究

Date: Friday, October 23, 2026

日期：2026年10月23日，星期五

Time: 15:15 - 16:00

时间：15:15 - 16:00

EIK1005

EIK1005

Title:

标题：

1143eTiP - Phase 1/2 Study of the Novel Werner Helicase Inhibitor EIK1005 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors, Including MSI-H or dMMR Tumors

1143eTiP - 新型Werner解旋酶抑制剂EIK1005作为单药治疗以及与帕博利珠单抗联合用于治疗晚期实体瘤（包括MSI-H或dMMR肿瘤）患者的1/2期研究

ePoster

电子海报

Title:

标题：

1010P - Analysis of the Safety, Tolerability, and PK of EIK1005, a Novel WRN Inhibitor

1010P - 新型WRN抑制剂EIK1005的安全性、耐受性及药代动力学分析

Date: Friday, October 23, 2026

日期：2026年10月23日，星期五

Time: 15:15 - 16:00

时间：15:15 - 16:00

About Eikon Therapeutics

关于 Eikon Therapeutics

Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing innovative medicines to address serious unmet medical needs. Eikon’s initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers.

Eikon 是一家处于临床后期阶段的生物制药公司，致力于构建一家全球化的 fully-integrated（全方位整合）组织，开发创新药物以满足尚未被充分满足的重大医疗需求。Eikon 的初始重点领域是肿瘤学，正在推进一系列针对高未满足需求领域的候选药物研发管线，这些药物有望最终成为治疗多种癌症的关键药物。

Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally-derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon’s vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster.

Eikon 部署其技术平台（包括其专有的单分子追踪系统），以开发内部衍生的创新疗法，同时借助其管理团队的深厚专业知识，许可引进具有潜力的资产。Eikon 的愿景是通过有目的地将传统生物学研究与先进工程技术相整合，更快地开发出更优质的药物，从而成为一代行业领导者。

For more information, visit www.eikontx.com..

更多信息，请访问 www.eikontx.com。

Forward-Looking/Safe Harbor Statements

前瞻性陈述/安全港声明

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts are hereby identified as forward-looking statements for this purpose. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words.

本新闻稿包含1995年《私人证券诉讼改革法案》“安全港”条款所定义的前瞻性陈述。出于此目的，本新闻稿中所有非历史事实的陈述均被认定为前瞻性陈述。这些陈述可通过诸如“旨在”、“预期”、“相信”、“可能”、“估计”、“期望”、“预测”、“目标”、“打算”、“也许”、“计划”、“有可能”、“潜在”、“寻求”、“将”等词语及其变体或类似表述来识别，尽管并非所有前瞻性陈述都包含这些词语。

Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential, safety, and efficacy of Eikon’s product candidates; the timing for anticipated data readouts; expected milestones and business objectives for 2026 and beyond, including Eikon’s anticipated presentations at the 2026 ESMO Congress; and other statements regarding Eikon’s future operations, financial performance, financial position, prospects, objectives, strategies and other future events..

本新闻稿中的前瞻性陈述包括但不限于以下方面的陈述：Eikon 候选药物的治疗潜力、安全性和有效性；预期数据公布的时间安排；2026 年及以后的预期里程碑和业务目标，包括 Eikon 预计在 2026 年欧洲肿瘤内科学会（ESMO）大会上的报告；以及有关 Eikon 未来运营、财务表现、财务状况、前景、目标、战略和其他未来事件的其他陈述。

These forward-looking statements are based upon management’s current expectations and assumptions, and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: our limited operating history; our significant net losses incurred since inception and the likelihood of incurring additional losses for the foreseeable future; our need for substantial additional funding; the early stage of development of many of our product candidates and the possibility that our product candidates may fail in development; our dependence on the success of our current product candidates; our ability to leverage our technology platform to enable more informed drug research and development; legal and regulatory risks; intellectual property-related risks; and those risks, uncertainties and other factors discussed under the caption “Risk Factors” and elsewhere in Eikon’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission (“SEC”) on August 13, 2026, and in other public filings with the SEC in the future..

这些前瞻性陈述基于管理层当前的预期和假设，并受多种风险、不确定性及其他因素的影响，可能导致实际结果和事件与前述前瞻性陈述所指示的情况产生重大且不利的偏差，其中包括但不限于：我们有限的运营历史；自成立以来产生的重大净亏损以及在未来可预见期间内可能继续发生额外亏损的可能性；我们对大量额外资金的需求；我们许多候选产品处于早期开发阶段，且存在开发失败的可能性；我们对当前候选产品成功的依赖；我们利用技术平台推动更明智的药物研发的能力；法律和监管风险；知识产权相关风险；以及在Eikon于2026年8月13日向美国证券交易委员会（“SEC”）提交的截至2026年6月30日的季度10-Q表格报告中标题为“风险因素”的部分及其他章节中讨论的风险、不确定性和其他因素，以及未来向SEC提交的其他公开文件中所讨论的相关因素。

As a result, you should not place undue reliance on any forward-looking statements. The forward-looking statements made in this press release speak only as of the date of this press release, and Eikon undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law..

因此，您不应过度依赖任何前瞻性陈述。本新闻稿中的前瞻性陈述仅反映本新闻稿发布之日的情况，除非法律另有要求，Eikon 不承担因新信息、未来发展或其他原因而更新此类前瞻性陈述的义务。

Contacts:

联系人：

Investors

投资者

Alfred “Freddie” Bowie, Ph.D., CFO

阿尔弗雷德·“弗雷迪”·鲍伊，哲学博士，首席财务官

ir@eikontx.com

ir@eikontx.com

Media

媒体

Colin Sanford

科林·桑福德

colin@bioscribe.com

colin@bioscribe.com